Protein-protein interactions in the HIV-1 replication cycle
Mapping the interactions between proteins derived from host and pathogen origins is essential for understanding the molecular mechanisms of host-pathogen interactions [1] [2] [3] [4] . Protein-protein interactions (PPI) play a crucial role in the replication of HIV-1 [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . HIV-1 infection results in an interplay between viral and host proteins or homodimeric/oligomeric viral protein interactions, resulting in a complex interaction network between various proteins [25, 26] . The HIV-1-Human Protein Interaction Database (HHPID) identified 1435 human genes encoding 1448 human proteins that interact with HIV-1 proteins, resulting in 2589 unique HIV-1-host protein interactions [27] [28] [29] [30] [31] [32] [33] . Thirty two percent of these are direct physical interactions as revealed from binding studies and 68% are indirect interactions such as upregulation through activation of signaling pathways. The database reveals that numerous human proteins interact with more than one HIV-1 protein. Using a quantitative scoring system termed mass spectrometric interaction statistics (MiST), 497 HIV-human PPIs involving 435 individual human proteins and 18 viral proteins have been identified [25, [34] [35] [36] [37] [38] [39] [40] .
HHPID reports 15 essential HIV-1 proteins [25, 31, [41] [42] [43] [44] (Figures 1 & 2) . Three fundamental proteins (Gag, Pol, Env) are encoded by the HIV-1 genome and they undergo proteolysis to form the mature proteins. Four structural proteins, matrix (MA), capsid (CA), nucleocapsid (NC) and p6, are products of the proteolysis of Gag. Env proteolysis results in the envelope proteins gp120 and gp41 [45, 46] . Pol encodes three enzymes: protease (PR), reverse transcriptase (RT) and integrase (IN). Encapsulated within the virus particle, the three Pol proteins play key functions in the viral replication upon infection. The remaining proteins (Vif, Vpr, Nef, Tat, Rev, Vpu) are accessory proteins [47] [48] [49] [50] . The database shows 43 different direct interactions of HIV-1 proteins with human proteins based on activity, binding, inhibition, cleavage, complexation, modulation, deglycosylation and upregulation. Only a part of these interactions are targets for peptide inhibitors and will be discussed here (Figure 2 ).
Peptides as a tool to study PPI
Understanding PPI requires thorough structural, biophysical and biochemical characterization using recombinant proteins. However, a major hurdle is the expression and purification of the interacting proteins. Some proteins are insoluble or toxic to the expressing host, resulting in low yields that hamper structural and quantitative studies. Using peptides for these studies provide many advantages relative to the recombinant proteins. Peptides derived from the interacting proteins enable determination of the specific interaction sites, the affinity and thermodynamic contribution (enthalpy vs entropy) in PPI [51] [52] [53] [54] . Chemical synthesis of the peptides makes it possible to overcome the expression and purification related problems of protein production [55] [56] [57] . This makes it technically convenient to study the PPI via a full-length protein and a peptide derived from the complementary protein in addition to the interaction between the two full-length proteins. Peptides derived from binding interfaces may bind weaker than the parent protein, partly due to loss of secondary structure. Modifications such as post-translational modifications (e.g., acetylation or phosphorylation) [58, 59] , labeling (e.g., fluorescein or biotin) or incorporation of nonnatural amino acids can be inserted specifically into a protein sequence only using chemical peptide synthesis [60, 61] . Peptides are an excellent model for binding studies of protein domains. Upon binding, they can undergo conformational change mimicking the native binding interface [62, 63] . This makes peptides a useful tool for discovering drug leads by modulating (either activating or inhibiting) PPI [64] [65] [66] [67] [68] [69] [70] . In this review, we present an overview of peptides derived from PPI from different stages of the HIV-1 replication cycle [71] and their implications for anti-HIV-1 drug design.
PART I: interactions between viral & host proteins
Interactions between the viral capsid & host membrane proteins
The initial contact between the virus and the host cell is made between the viral glycoprotein gp120 (originating from the Env polyprotein, PDB: 3DNL, Figure 3A ) and the cell surface receptor CD4 [72, 73] . CD4 is a host glycoprotein expressed on the surface of T helper cells, regulatory T cells, macrophages, monocytes and dendritic cells. The binding of a highly conserved, nonglycosylated region of gp120 to CD4 results in the viral insertion into the host membrane [74] [75] [76] . Upon association with another viral envelope protein, gp41 (PDB: 2ZFC, Figure 3B ), which mediates viral entry through membrane fusion, binding to CD4 occurs. This results in a conformational change that allows gp120 to bind to the coreceptors CCR5 or CXCR4 [77, 78] ; belonging to the family of G protein-coupled receptors and chemokine receptors [79] [80] [81] . The viral insertion causes an additional conformational change in the heptad repeat regions (HR1 and HR2) of gp41 [82] , resulting in the entry of the viral capsid into the host cell via a fusion Interactions of HIV-1 proteins as targets for developing anti-HIV-1 peptides Review pore [83] . This leads to the generation of epitopes for neutralizing antibodies that prevent chemokine receptor binding [84, 85] . Two inhibitors of fusion and entry are currently used in the clinic. Approved in 2003, the 36-mer peptide inhibitor T20 (Enfuvirtide) blocks a critical conformational change in gp41 responsible for membrane fusion [86] . Maraviroc is a small molecule antiretroviral drug, approved in 2007, which inhibits the interaction between gp120 and CCR5 [86] .
Peptides derived from HIV-1 Env & host proteins interactions
The HIV inhibiting peptide database (HIPdb) reveals 110 HIV inhibitory peptides that target the interactions of the viral Env proteins. They aim to prevent the interactions between the virus and cellular cofactors by binding either viral envelope proteins or host proteins [87, 88] . Table 1A shows the best HIV-1 inhibitory peptide based on the prediction of antigenicity method for inhibiting Env proteins. The HIV-1 envelope protein gp41 fragment peptide (residues 568-588) is derived from the N-heptad region of gp41 Env ectodomain [89] . It specifically binds the phospholipid membrane thereby inhibiting the viral-cell fusion process. Microcalorimetric titrations revealed that a 22-resides tyrosine-sulfated peptide (S22 peptide) derived from the N-terminus of CCR5 showed a strong interaction with the gp120-CD4 complex with K d = 2.2 μM (Table 1B) . The process is both entropically and enthalpically favorable. No binding was observed between the gp120-CD4 complex and an identical peptide lacking the sulfated tyrosine residues [90, 91] .
HIV-1 gp120 & CXCR4 interactions
One of the functions of gp120 is tethering of the virus to the cellular co-receptor CXCR4. CXCR4 binds the bridging sheet and V3 loop of gp120 [92, 93] .
The binding between CXCR4 and gp120 involves a conformational rearrangement of gp120. The soluble synthetic peptide, CX4-M1, functionally mimics the HIV-1 co-receptor CXCR4 [85, 94] . The interaction interface between gp120 and its cellular co-receptor partner CXCR4 is between the V3 loop of gp120 and the extracellular loops (ECLs) of CXCR4. The CX4-M1 peptides are derived from the ECL region of CXCR4 from different HIV1 strains and binding was determined via direct ELISA [95] . The binding affinities between the peptides and the protein were measured by surface plasmon resonance (SPR) (Table 1C) . To confirm specific binding, CX4-M1 was competed with a specific antibody, mAb447-52D, that recognizes the V3 loop of gp120. A peptide binding assay with CX4-M1 and V3 loop peptides [279] ; (B) NTD of HIV-1 gp41 trimer (PDB: 2ZFC) [280] ; and (C) HIV-1 RT with DNA (PDB: 3V4I) [281] . The viral enzyme reverse transcriptase HIV-1 reverse transcriptase (RT) produces a viral cDNA based on the viral RNA (PDB: 3V4I, Figure 3C ). The DNA is later integrated into the host cell genome [96] .
RT is a heterodimeric protein with two asymmetric chains termed p51 and p66 [97] . HIV-1 RT has three main activities: RNA-directed DNA polymerization, DNA-directed RNA polymerization and exonuclease via degradation of RNA [98] . RT is the target of numerous small molecule antiretroviral drugs used in the clinic [99] . AZT is a Nucleoside analog RT Inhibitor Interactions of HIV-1 proteins as targets for developing anti-HIV-1 peptides Review (NRTI) that acts as a chain terminator of growing DNA strand and was approved as an anti-HIV drug in 1987. In 1996, Nevirapine was approved as the first non-nucleoside RT inhibitor (NNRTI) that inhibits the RT polymerization activity.
The HIV-1 RT & A3G interaction
During reverse transcription, the human cytidine deaminase APOBEC3G (A3G) eliminates HIV-1 infection by inducing deamination of the cytosine residues to uracil in the negative viral DNA strand [100] [101] [102] [103] [104] [105] [106] [107] [108] . Using a cell-based co-immunoprecipitation (coIP) assay, the direct interaction of A3G with RT was detected both in transfected cells and in the produced viruses. No other viral components are needed for this interaction. Deletion analysis with a series of T7-tagged RT-deletion mutants (T7-RT 1-243 , T7-RT 1-323 and T7-RT ) determined that the RT-binding domain is located at the N-terminal region of A3G [101, 109, 110] . The polypeptide A3G inhibited the interaction between A3G and the viral RT (PDB: 3VOW, Figure 4A , Table 2A ) [101] . The RT-binding polypeptide inhibited the anti-HIV effect of A3G on RT. Competitive coIP in cells co-expressing both RT and A3G using several A3G derived polypeptides showed that A3G significantly disrupted the A3G-RT binding.
Interactions of the HIV-1 integrase
HIV-1 integrase (IN) plays one of the key roles in the viral replication cycle by integrating the reverse transcribed viral cDNA into the host genome (Figure 1 ) [111] [112] [113] [114] [115] . It has three functional domains responsible for integration process: the N-terminal domain (NTD), the catalytic core domain (CCD) and the C-terminal domain (CTD) [116, 117] . IN has two enzymatic activities: first, 3′-end processing in the cytoplasm [111, 118] in which two IN dimers [119] bind the long terminal repeats (LTR) of the viral DNA and remove a pGT dinucleotide from the 3′-end of each strand. After nuclear transport [120, 121] , the strand transfer reaction is carried out by an IN tetramer [122] [123] [124] resulting in integration of the viral DNA into the host genome. Finally, the single-stranded gaps (A) Env and CD4 interaction HIP962 EINCTRPNNNTRKSIRIQRGPGRAFVTIGKIGNMRQAHCNIS [87, 88] HIP963 CTRPNNNTRKSIRIQRGPGRAFVTIGKIGNMRQAHC [87, 88] HIP964 ESVKITCARPYQNTRQRTPIGLGQSLYTTRSRSIIGQAHCNIS [87, 88] HIP965 EINCTRPNNNTRKSIHIGPGRAFTTGEIIGDIRQAHCNIS [87, 88] HIP966 ESVVINCTRPNNNTRRRLSIGPGRAFYARRNIIGDIRQAHCNIS [87, 88] HIP953 WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFRS [87, 88] HIP958 YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF [87, 88] HIP959 YTSLIHSLIEESQNQQEKNEQELLELDKWASLANAA [87, 88] HIP1016 WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFR-SLTVWGIKQLQARILAVERYLK [87, 88] (B) gp120 and CCR5 interaction S22 MDYQVSSPIY(SO 3 -)DINY(SO 3 -)YTSEPSQK [90, 91] (C) gp120 and CXCR4 interaction (ECL1)CX4-M1 (ECL1) 97 between the viral DNA and target DNA are repaired by the host DNA repair machinery [125] [126] [127] . The equilibrium between dimeric and tetrameric IN is of extreme importance in the integration process, making it an attractive target for drug design [69] . In 2007, Raltegravir was the first IN inhibitor approved for clinical use. Another IN inhibitor, Elvitegravir, was approved for clinical use in 2012 [128, 129] . Both inhibitors block IN by binding directly to the IN-DNA complex formed during the integration of the viral DNA into the host cell genome [128, 129] .
Peptides derived from the dimerization interface of IN
The dimerization interface of IN is an excellent starting point for peptides that would inhibit dimer formation [130] [131] [132] . Several peptides have been designed (PDB: 3L3U, Figure 5A , Table 2B ) but due to relatively low binding affinity to IN, they did not succeed in disrupting the dimeric IN and hence were not efficient inhibitors. Some of the peptides (IN [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] , IN [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] , IN [171] [172] [173] [174] [175] [176] [177] [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] and IN [196] [197] [198] [199] [200] [201] [202] [203] [204] [205] [206] [207] [208] [209] [210] ) showed very mild IC 50 for both 3′-processing and strand transfer in vitro. IN , which is derived from IN, inhibited IN at 600 μM concentration by partly blocking the active site. The peptide inhibited the catalytic activity of IN by binding it through a protein-peptide coiled-coil structure [130, [133] [134] [135] . Two peptides derived from the α1 and α5 helices of the CCD, (INH1 and INH5) specifically bound to the dimerization interface of the CCD of IN [136] . The IC 50 for 3′-processing by INH1 was 250 μM and by INH5 was 11 μM. By inhibiting the 3′-endonuclase activity of IN with IC 50 values in the low micromolar range, three peptides (α1, α5, α6) also inhibited the IN dimerization [137] . The truncated peptide (NL6-5) and retro-inverso-peptides (RDNL6, RDNL9) retained the inhibitory activity by disrupting the IN dimer and tetramer formation [138, 139] All the peptides were derived from the CCD of IN, which is the only domain that mediates IN dimerization ( Figure 5A ) [138, 139] . Targeting host proteins is risky since it may affect cell viability and produce undesired toxicity. Therefore, the best strategy is to study the interactions between IN and host proteins by finding peptides derived from the INbinding region of the cellular proteins. These peptides will potentially bind the viral protein and inhibit the interaction with less potential for undesired side effects.
The IN-LEDGF/p75 interaction
In addition to binding the viral DNA [140] [141] [142] , IN interacts strongly with the cellular transcriptional co-factor LEDGF/p75 [143] . LEDGF/p75 tethers the IN-DNA complex to the host chromatin, where the final integration steps take place [140, [144] [145] [146] [147] [148] [149] [150] [151] . The IN-LEDGF/p75 is a crucial interaction in the replication cycle, making it as a fundamental target for anti-HIV drug design. The structure of IN CCD in complex with the LEDGF/p75 IN binding domain (IBD) shows a pseudo two-fold symmetry where an IN CCD dimer binds two LEDGF/p75 IBD at either side (PDB: 2BJ4, Figure 5B ) [152] . The IBD interacts with IN via two loops. Our lab rationally designed peptides based on these loops and shorter variants (LEDGF/p75 [361] [362] [363] [364] [365] [366] [367] [368] [369] [370] , LEDGF/ p75 [402] [403] [404] [405] [406] [407] [408] [409] [410] [411] ) [69] . All of these bound IN with micromolar affinities and inhibited the in vitro enzymatic activities both in presence and absence of LEDGF/p75 (Table 2B ). In addition, these peptides inhibited the integration of viral cDNA and HIV-1 replication in infected cells, by shifting the IN oligomerization equilibrium toward a stable tetramer in the cytosol. Further studies including homology modeling, alanine scan and NMR analysis revealed that all the residues of LEDGF/p75 361-370 and LEDGF/p75 402-413 are important for optimal binding and inhibition of IN ( Figure 5B ) [69, [153] [154] [155] [156] . A library of cyclic peptides (CPs) derived from LEDGF/p75 [361] [362] [363] [364] [365] [366] [367] [368] [369] [370] was screened for in vitro IN binding and inhibition [155] . One of these peptides, c(MZ4-1) was a potent and stable inhibitor of IN in vitro. NMR and docking studies revealed that c(MZ4-1) possessed a conformation almost identical to the parent IN-binding loop from the IBD of LEDGF/p75. An AlphaScreen assay with these peptides also accounted for IN-LEDGF/p75 interaction [157] .
A random peptide phage display strategy was adopted to identify a linear peptide, LEDGF/p75 , that bound specifically to the IBD of LEDGF/p75. Based on this, small CPs (CP64 and CP65) inhibitors of the IN-LEDGF/p75 interaction (IC 50 for CP64 is 35.88 μM and IC 50 for CP65 is 59.89 μM) were developed. These peptides inhibited HIV replication in different cell lines without displaying toxicity (Table 2C ) [158] . Saturation transfer difference (STD)
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Alanine scan: Screening technique for determining of the contribution of specific residues to the function and interactions of a protein. Each residue is sequentially replaced by alanine and the function/interaction of the mutant peptide/protein is compared with the parent peptide. Loss of function/interaction means that the original residue was important for the binding/activity. Alanine is used since it is the simplest chiral residue and thus mimic a loss of a side chain without a conformational change or an introduction of a new function.
Cyclic peptides: Cyclization improves the pharmacological properties of peptides. They are conformationally rigid, resistant to protease degradation and in many cases have improved affinity and specificity as well as cell penetration properties.
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Stapled peptides that target IN-mediated integration & the IN-LEDGF/p75 interaction
Two-domain crystal structures of IN show that the two monomers of dimeric IN are tethered via strong helix-helix (α1:α5′ and α5:α1′) interactions [159, 160] . Using the 'sequence-walking' strategy, two potent IN inhibitors termed NL6 and NL9 [161] were revealed. NL6 has an α-helical structure and is part of the α1 helical domain. A series of hydrocarbon stapled peptides derived from NL6 (NLH2-NLH16, NLX1, NLX2) enhanced interfacial interaction and cellpermeability compared with the parent NL6 peptide through stabilization of the α1 domain [162] as confirmed by CD studies. Increasing the α-helical content also increased the IN inhibitory activity at the 3′-processing step, inhibition of the strand transfer reaction and the IN-LEDGF/p75 interaction, cytoprotective activity (EC 50 ), cell death activity (CC 50 ) and therapeutic index (ratio of CC 50 to EC 50 ). Combining pairs of α-helical peptides effectively inhibited IN catalytic activities. The most active pair was unstapled NLH5 and stapled NLH6 (IC 50 values of 9 ±1 μM for 3'-processing and 6 ±1 μM for strand transfer [155] ). The pairs were designed with a covalent hydrocarbon staple spanning i and i + 4 residues that did not show inhibition in the alanine scan [163, 164] . Most of the stapled peptide pairs inhibit the IN-LEDGF/p75 interaction. Six peptides (NLH2, NLH3, NLH5, NLH6, NLH15, NLH16) inhibited HIV-1 replication in MT-4 cells. Fluorescein-tagged NLH6 (termed NLX-1) penetrated cells and inhibited the target IN. MT-4 cells showed significant cellular uptake of NLX-1, which was localized mainly to the cytoplasm with minimum distribution to the nucleus. The cell-permeability and enhanced potency of the stapled peptides makes them lead IN inhibitors.
Mapping HIV-1 Gag & host cellular proteins interactions
HIV-1 Gag is a viral polyprotein expressed during the late phase of the replication cycle. Cleavage of Gag by the viral PR produces the structural proteins of the mature virion: the matrix (MA), capsid (CA) and nucleocapsid (NC) proteins. MA is the N-terminus of Gag, followed by a CTD termed p6 and two spacer regions that separate CA from NC and NC from p6. The Gag products take part in viral self-assembly and release of virions from the infected cells, thus making it critical for viral particle morphogenesis and replication within the living cells [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] . The maturation inhibitor Bevirimat is currently in clinical trials. It targets the Gag protein to prevent PR-mediated cleavage at specific Gag sites and also binds CA to prevent core formation [175] .
The interaction between Gag p6 & human Tsg101
HIV-1 p6 is a Gag cleavage product that plays an important role in regulating capsid processing, facilitating virus budding and incorporation of the viral accessory protein R (Vpr) into virions. These processes require interactions between the human tumor susceptibility gene 101 (Tsg101) protein and the CTD of p6 [176] . Tsg101 is a part of the endosomal sorting complex required for transport-I (ESCRT-I), which assists the ubiquitylation of Gag and facilitates viral assembly and budding [177] [178] [179] [180] . Successful HIV-1 budding requires an interaction between the tetrapeptide PTAP, derived from residues 3-6 in p6, with the ubiquitin E2 variant (UEV) domain of Tsg101 (PDB: 3OBU, 3OBX, Figure 6 ). Blocking this interaction inhibits virion formation [181] [182] [183] .
Peptides containing the PTAP motif are potential inhibitors of the interaction between Gag p6 and Tsg101. A peptide derived from p6 5-13 bound Tsg101 (Table 3A ) [184] . NMR studies showed that the peptide bound to Tsg101 in a groove that interacts with the PTAP residues with K d = 3 μM [177, 183] . The structure showed that binding of E2 ubiquitin-conjugating enzymes to UEV domain of Tsg101 was hampered upon PTAP binding (Figure 6 ). Structure activity relationship (SAR) studies of this peptide, which included conversion to P 3 polycyclic oxime derivatives in the PTAP domain, improved binding to Tsg101 by 15-to 20-fold [184] [185] [186] .
To develop effective competitive inhibitors, a technique for genetically selecting CPs that inhibit specifically the p6 Gag-Tsg101 interaction was used [187] . This technique, called SICLOPPS (split intein-mediated circular ligation of peptides and proteins), allowed identification of new CPs that specifically blocked the p6 Gag-Tsg101 interaction and consequently inhibited HIV replication. After several rounds of screening, the selected CPs had no resemblance to the original sequence of the interacting sites in either p6 Gag or Tsg101. Of these, CP11 inhibited the formation of virus-like particles (VLP) in cultured cells with IC 50 of 7μM and showed better stability compared with the linear p6 [5] [6] [7] [8] [9] [10] [11] [12] [13] .
The p6 Gag & cyclophilin interaction
Another partner of p6 Gag is the cellular cyclophilin A (CypA) protein, which acts as a prolyl isomerase (PPIases). CypA also acts as a molecular chaperone and assists protein folding, assembly and transportation processes. CypA is incorporated into newly budding particles of HIV-1 and thus can be considered as Interactions of HIV-1 proteins as targets for developing anti-HIV-1 peptides Review a key target in future antiretroviral therapy [188] . p6 contains a relatively high content of proline residues, at positions 5, 7, 10, 11, 24, 30, 37 and 49. Proline cis/ trans isomerism was observed for all these proline residues and more than 40% of all p6 Gag proteins show at least one proline in cis-orientation. 2D proton NMR of full length p6 Gag or p6 Gag-derived peptides with CypA revealed that it interacts with all proline residues of p6 Gag through a prolyl-peptidyl cis-trans isomerase (PPIase).
The modulation of HIV-1 p6 function by CypA was explored by the synthesis of full length p6 and several p6 fragments (p6 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] , p6 , p6 23-32 , p6 32-42 , p6 [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] and p6 ) and by using NMR and Surface Plasmon Resonance (SPR) (Table 3A ) [188] . Catalytic amount of CypA is sufficient to interact with all the proline residues of p6 (molar ratio 1: 283; Table 3A ) and hence PPIases activity in vitro. However, there was low affinity binding of CypA to p6 fragments compared with binding to full-length p6. Another important inhibitor of CypA is cyclosporine A which was found to suppress both the production and the release of new virions [189, 190] .
Interactions of HIV-1 Tat
The HIV-1 trans-activator of transcription (Tat) protein is a small viral auxiliary protein that contains 101 or 86 residues, depending on the HIV strain [191, 192] . The Tat protein can be divided into six regions: an acidic region (residues 2-11), a cysteinerich domain (residues 22-37), the hydrophobic core (residues 38-46), a basic region (residues 47-57), the glutamine-rich domain (residues 58-72) and the RGD motif (residues 72-86) [193, 194] . The basic region of Tat binds to the negatively charged mRNA in the Tat-activation region (TAR) [195, 196] . The binding of Tat to TAR promotes a prolongation of the transcription due to conformational change of the TAR during binding of host cell kinases that phosphorylate the RNA polymerase II complex. The six Arginine residues in Tat [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] are crucial for Tat-TAR recognition [197] [198] [199] [200] .
The peptide Tat 47-57 specifically disrupted the TAR-RNA recognition by blocking the production of viral transcript and also interrupted the formation of two cellular cofactors, cyclin T1 and its cognate kinase CDK9, responsible for transcriptional elongation from the viral long terminal repeat (LTR) [197, 198, [201] [202] [203] [204] [205] . Increasing the number of Arginine residues on the hairpin scaffold of Tat-derived peptides dramatically decreased the specificity for binding the TAR-RNA. In contrast, fewer Arginine residues in a Tat-derived peptide of the same length increased the TAR-RNA binding specificity. Arginine-rich Tat peptides have a higher resistance to degradation by proteases (Table 3B ) [197, 198, [201] [202] [203] [204] [205] .
The Tat-p53 interaction
The cellular tumor suppressor p53 is a homotetrameric transcription factor that induces cell cycle arrest or apoptosis upon oncogenic stress [206] . NMR and x-ray crystallography revealed that the p53 tetramerization domain (p53 Tet; residues 326-355) has a dimer of dimers structure [207, 208] . Depending on its concentration, p53 Tet exists in equilibrium among different oligomeric forms [209, 210] . p53 inhibits Tat-mediated LTR transcription [211] . The viral Tat binds p53 Tet as was shown by yeast two-hybrid system [209, 212] . The CTD of p53 (residues 341-355) interacts specifically with the Tat residues 49-57 in the arginine-rich motif (ARM) [212] . Tat 73-86 can bind p53 with the assistance of cellular proteins such as NF-κB and CBP/p300, as observed by in vivo experiments [191, 213, 214] .
To quantitatively understand the molecular basis of Tat-p53 interaction during HIV-1 replication cycle, our laboratory synthesized Tat-derived peptides (Tat and Tat [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] ) and studied their binding to the p53 tetramerization domain (Table 3C ) [214] . The binding between p53 Tet and Tat [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] is purely cooperative and is temperature-dependent. NMR studies revealed that E343 and E349 from p53 Tet are the major Tat [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] binding residues. The binding mechanism involves electrostatic interactions [214] .
The interaction of HIV-Vif with the host cellular protein APOBEC3G
The HIV-1 virion infectivity factor (Vif) is required for the virus replication [215, 216] . Vif counteracts A3G future science group Review Chandra, Maes & Friedler by targeting it for proteosomal degradation and by direct inhibition of its enzymatic activity (PDB: 3IR2, Figure 4B ) [217] . Both activities involve a direct interaction between Vif and A3G and thus their inhibition may rescue the antiviral activity of A3G and inhibit HIV-1 propagation [218] [219] [220] . Vif binding to (A) Interaction between MA and TCR Gag p6 and Tsg101 interaction p6 5-13 PSAP peptides PEPTAPPEE [177, [183] [184] [185] [186] p6 Gag and CypA interaction p6 1-52 LQSRP5EPTAPPEESFRFGEETTTPSQKQEPIDKELY-PLASLRSLFGSDPSSQ [188] [189] [190] p6-UEV interaction Pep#6 TNWYGSG-W [184] [185] [186] Pep#8 VLRVHSG-W [184] [185] [186] Pep#11 IYWNVSG-W [184] [185] [186] Pep#16 TLLVYSG-W [184] [185] [186] Pep#112 DGPRGPSTSG-W [184] [185] [186] Pep#119 GCPFPPSYSG-W [184] [185] [186] Pep#120 PGPVTPGFSG-W [184] [185] [186] Pep#122 ARPNRPCRSG-W [184] [185] [186] Pep#126 LVPWMPRPSG-W [184] [185] [186] Pep#127 PGPCSPVGSG-W [184] [185] [186] p6 binding p6 1-52 LQSRP5EPTAPPEESFRFGEETTTPSQKQEPIDKELY-PLASLRSLFGSDPSSQ [188] [189] [190] p6 1-21 LQSRPEPTAPPEESFRFGEET [188] [189] [190] p6 1-14 LQSRPEPTAPP11EES [188] [189] [190] p6 23-52 TPSQKQEPIDKELYPLASLRSLFGSDPSSQ [188] [189] [190] p6 23-32 TPSQKQEPID [188] [189] [190] p6 32-42 DKELYPLASLR [188] [189] [190] 
(B) Interactions of Tat with host proteins
Tat derived peptides Tat 47-57 YGRKKRRRQRRR [197, 198, [200] [201] [202] [203] [204] [205] AghTat † YG-Agh-KK-Agh-Agh-Agh-Q-Agh-Agh-Agh AgbTat † YG-Agb-KK-Agb-Agb-Agb-Q-Agb-Agb-Agb
(C) The Tat-p53 interaction
Tat derived peptides Tat 1-35 MEPVDPNLEPWKHPGSQPTTACSNCYCKVCCWHCQ [212] [213] [214] Tat 47-57 YGRKKRRQRRR [212] [213] [214] Tat 30-49 CCWHCQLCFLKKGLGISYGK [212] [213] [214] Tat 56-76 RGPPQGSKDHQTLIPKQPLPQW [212] [213] [214] Tat 65-80 HQVSLSKQPTSQSRGD [212] [213] [214] Tat 73-86 PTSQSRGDPTGPKE [212] [213] [214] P53 derived peptides p53 326-355 EYFTLQIRGRERFEMFRELNEALELKDAQA [211] [212] [213] [214] p53 326-355 R342A EYFTLQIRGRERFEMFAELNEALELKDAQA [211] [212] [213] [214] p53 326-355 L344P EYFTLQIRGRERFEMFREPNEALELKDAQA [211] [212] [213] [214] p53 326-355 L344A EYFTLQIRGRERFEMFREANEALELKDAQA [211] [212] [213] [214] p53 326-355 E346A EYFTLQIRGRERFEMFRELNAALELKDAQA [211] [212] [213] [214] p53 340-351 MFRELNEALELK future science group
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A3G results in polyubquitination and degradation of A3G by forming a E3 ubiquitin ligase complex consisting of ElonginB and C, Cullin5 and RING finger protein 1 [221, 222] . The mutation K128D in A3G abrogated the interaction with Vif [223, 224] .
The peptides Vif [14] [15] [16] [17] , Vif [22] [23] [24] [25] [26] , Vif [40] [41] [42] [43] [44] and Vif [69] [70] [71] [72] inhibited the A3G-Vif interactions (Table 3D ) [225] . Deletion mutagenesis of A3G also showed that Vif and Vif peptides are critical for the interaction [226] . An in vitro Vif-A3G binding assay between GST-tagged Vif and His-tagged A3G and a Fluorescence Resonance Energy Transfer (FRET) assay between GST-Vif and biotinylated A3G confirmed their interactions (Table 3D ) [227] .
Mapping the Vif-A3G interaction by using peptide arrays resulted in defining the precise binding interface (Table 3D ) [226] [227] [228] [229] . A3G bound nine Vif-derived peptides from three distinct regions in Vif: residues 8-45 from the NTD, residues 154-192 from the CTD containing the conserved motif 161 
PPLP
164 and a central region between residues 83-99 [230, 231] . The A3G-derived peptides A3G [143] [144] [145] [146] [147] [148] [149] [150] [151] [152] [153] [154] [155] [156] [157] , A3G and A3G [263] [264] [265] [266] [267] [268] [269] [270] [271] [272] [273] [274] [275] [276] [277] bound fulllength Vif and Vif-CTD. The peptide array experiment revealed that peptides A3G 31-52 , A3G [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] [176] [177] [178] [179] [180] , A3G [211] [212] [213] [214] [215] [216] [217] [218] [219] [220] [221] [222] [223] [224] [225] , A3G [263] [264] [265] [266] [267] [268] [269] [270] [271] [272] [273] [274] [275] [276] [277] and A3G 331-367 also bound to Vif.
The interactions of Vpr with host cellular proteins
The viral protein R (Vpr) is the only virion associated regulatory protein and is not a component of the virus polyprotein precursors. It assists the nuclear import of the preintegration complex (PIC) in nondividing host cells [232] . Vpr is crucial for effective HIV-1 infection of target CD4 + T cells and macrophages [233] [234] [235] . Vpr interacts Vpr 87-96 RRARNGASRS [236, 240, 241] C45D18 DTWPGVEALIRILQQLLFIHFRIGCQHC [240] [241] [242] Vpr H1 TLELLEELKNEAVRHFPR [242] Vpx H1 EAFDWLDRTVEAINREAVNH with numerous cellular proteins in order to perform its nuclear import and G 2 cell cycle arrest functions.
Interaction between Vpr & CypA
One of the key Vpr interacting protein is cyclophilin A (CypA) [236] . Cis-trans prolyl isomerization of the highly conserved proline residues in Vpr, such as Pro5, Pro10, Pro14 and Pro35, is catalyzed by CypA. SPR experiments showed that the heptapeptide CypA 32-38( 32 RHF-PRIW 38 ) mediates the binding between CypA and the N-terminal region of Vpr [237] . P35A mutation disrupted the Vpr-CypA interaction. In the mutant peptide Vpr [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] (R80A), the replacement in the C-terminal region of Vpr hampered the co-IP of Vpr with CypA [238, 239] .
The above observations together with the significant amount of CypA in the virion [240] led to the design of Vpr-based peptides to study the Vpr -CypA interaction (Table 3E ) [241, 242] . SPR and ITC studies revealed the strong binding affinities of C-terminal Vpr [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] R76Q, V83I, R80A, T841 (K d = 4.7 μM) as compared with the wild type peptide. NMR studies revealed that the mutations did not influence the secondary structure of the C-terminal binding domain of Vpr.
The interaction between Vpr & the WXXF motif of host cell proteins
The conserved WXXF motif of uracil-DNA-glycosylase mediates the intracellular binding of Vpr with uracil DNA glycosylase. Many WXXF-including peptides have domain-specific interactions with Vpr. The fusion of the WXXF dimer to the chloramphenicol acetyl transferase (CAT) gene demonstrated that the WXXF dimer-CAT construct induced CAT activity inside the virions through Vpr-dependent docking [243] . Phage display peptide screening predicted that more than 90% peptides having consensus motif WXXF efficiently binds Vpr protein [243, 244] . Similarly, Vpr binding peptides from GST-Vpr panning also revealed a WXXF consensus motif [245] . Nine peptides were found to bind Vpr (Table 3E ) [243] .
The Vpr interaction with cell-surface α V β 3 in endothelial cells
Vpr targets mitochondrial membranes to trigger apoptosis and cell death. The internalization of cyclic RGD in endothelial cells for cellular apoptosis is mediated by the cell surface receptors α V β 3 integrins. The Vpr induced apoptotic cell death involves the interactions of Vpr with the voltage-dependent anion channel (VDAC) and the adenine nucleotide translocator (ANT) [246, 247] . The VDAC and ANT interaction is based on permeability transition pore (PTP) as a result of dynamic multiprotein complex formation at inner and outer mitochondrial membrane contact sites.
A TEAM-VP (Targeted to Endothelial Apoptogenic Mitochondrio-active Vpr-derived Peptide) peptide was designed based on α V β 3 binding and endothelial apoptogenic sequences derived from the mitochondria active portion of Vpr. TEAM-VP peptide is combined with a tumor blood vessel RGD-like 'homing' motif and a mitochondrial membranes permealization (MMP)-inducing sequence. It is composed of the cysteine mediated CP sequence GGCRGDMFGC and a Vpr 67-82 sequence derivative (Table 3E ). The cyclic core 'GGCRGDMFGC' of TEAM-VP specifically bound to VDAC and ANT and internalized into α V β 3 -expessing cells through its cyclic-RGD motif. [248] .
PART II: interactions between viral proteins
The Env-MA interaction
The matrix protein p17 (MA) originates from the Gag precursor protein, p55
gag [249] . It is N-terminally myristylated and binds to the viral inner membrane or the inner leaflet of the plasma membrane (PM) of the infected cells [250] . MA is involved in nuclear import of the viral DNA [251] . A specific interaction between p17 and Env was revealed by the co-expression of Env proteins that influenced the assembly of Gag particles. The membrane-proximal amino terminus of p17 in the Gag precursor closely associates with the membrane in the mature particle indicating that p17 participates in the specific Env incorporation into the viral particles [252] .
Several p17 peptides (p17 l-12 , p17 [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] , p17 30-52 , p17 , p17 and p17 [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] ), derived from all the six parts of p17, were synthesized (Table 4A ) [253, 254] . The antigenic epitopes was examined for anti-HIV-1 p17 antibody (p17 Ab) in the serum of an HIV1 carrier. p17 l-12 , p17 [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] , p17
30-52 were highly recognized in the serum and led to inhibition of virus multiplication as tested using ELISA. The purified antibodies obtained from the patient using the p17-derivated peptide immunoaffinity columns confirmed that the reactivity of p17 Ab to p17 was the highest among the antibodies.
The Gag-PR interaction PR cleaves the Gag and Gag-Pol precursors into active viral proteins such as p1 gag , p2 gag , p6 gag , p7 gag , p17 gag and p24
gag [45, [255] [256] [257] . The cleavage of the Gag precursors is necessary for maturation and HIV-1 infectivity. p2 gag is an inherent suicidal inhibitor of PR due to its strong in vitro inhibition of the proteolytic cleavage of the recombinant Gag precursor into functional structural units (p17 gag and p24 gag ) [258] . After the viral maturation, p2 gag future science group
Interactions of HIV-1 proteins as targets for developing anti-HIV-1 peptides Review inhibits PR activity in released viral particles and thus blocks the autolysis of HIV-1 virions. PR is one of the most common anti-HIV drug targets and many FDA approved anti-HIV drugs are PR inhibitors [86, 97] . The nonapeptide (AEAMSQVTN) derived from the N-terminus of p2 gag inhibited HIV-1 PR activity in vitro to prevent autolysis of the virion after sequential processing and reorganization of the virion core (Table 4B ) [258] . Further SAR studies with p2 gag revealed that alanine replacements (M4A and T8A) and deletion of Asn9 from the nonamer (AEAMSQVTN) decreased the PR inhibitory properties. However, the other mutated peptides did not have inhibitory activity.
The Vif-PR interaction
Vif blocks the cleavage activity by directly interacting with PR. Vif stably blocks the premature activation of PR in cytoplasm, which is circumvented during particle assembly [259] . The NTD of Vif (residues 1-96) inhibits the PR cleavage in vitro and in bacteria. Both Vif and PR are present in the mature virions [260] . Vif regulates PR in the virion at the early stage of infection [260] . Several Vifderived peptides inhibited PR-mediated cleavage of Gag in vitro and during viral protein expression in peripheral blood lymphocytes [261] . Vif specifically inhibited the Vif-PR interaction in vitro and blocked the production of viruses in HIV-1-infected cells [262, 263] . Vif [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] inhibited PR dimerization. Two PR-derived peptides PR [1] [2] [3] [4] [5] [6] [7] [8] [9] and PR [94] [95] [96] [97] [98] [99] abrogated Vif function as an A3G neutralizer and inhibited Vif-PR binding in a dose-dependent manner [264] . This means that PR [1] [2] [3] [4] [5] [6] [7] [8] [9] competed with PR for the Vif binding site.
Vpr interactions with RT & IN
RT, IN and Vpr are in close spatial proximity within the PIC, allowing them to interact with each other [265] .
The interaction between RT and IN involves the singlestranded viral RNA copied into integration-competent double-stranded DNA by RT, DNA polymerase and ribonuclease H (RNaseH). Then the PIC is imported to nucleus by IN and Vpr for integration [266] . RT and IN physically interact with each other and the fulllength Vpr and its isolated CTD can interfere with the IN-mediated integration activity in vitro [267] .
A library of Vpr-derived peptides was screened for their ability to bind directly to RT and IN in vitro and to inhibit their enzymatic activities (Table 4B ) [265] [266] [267] . Dot-blot binding assay showed that the C-terminal Vpr [253, 254] p17 12-29 ELDKWEKIRLRPGGKKQY [253, 254] p17 30-52 KLKHIVWASRELERFAVNPGLLE [253, 254] p17 53-87 TSEGCRQILGQLQPSLQTGSEELRSLYNTIAVYC [253, 254] p17 87-115 CVHQRIDVKDTKEALDKIEEEQNKSKKKA [253, 254] p17 115-132 AAADTGNNSQVSQNY [253, 254] Env V3 NCTRPNNNTRKSIHIGPGRAFYTTGEIIGDIRQAHC [253, 254] 
(B) Interactions of Protease
Protease and Gag interaction p2 gag pep# AEAMSQVTNTATIM [257, 258] Nona p2 gag pep# AEAMSQVTN [257, 258] p2 gag pep# mutant1 AEAMSQ [257, 258] p2 gag pep# mutant2 AEAMSQV [257, 258] p2 gag pep# mutant3 AEAMSQVT [257, 258] p2 gag pep# mutant4 VTN [257, 258] p2 gag pep# mutant5 VTNTATIM [257, 258] Protease-Vif interaction [65] [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] .
Conclusion & future perspective
In this review, we described the PPI in the HIV-1 replication cycle that are targets for inhibition by peptides and from which inhibitory peptides were derived. [84] [85] [86] 268, 269] . Current research in anti-HIV drug design is focused on stabilizing lead peptides using different strategies such as cyclization, peptoids and more [268] [269] [270] [271] [272] [273] .
Peptides serve as excellent starting points for the design of peptidomimetics and the development of new small molecule drug leads based on their sequences and conformations. Currently, many of the FDA-approved anti-HIV drugs in the clinic, such as Indinavir, Ritonavir, Saquinavir and Lopinavir are the result of gradual conversion from a peptide to a small molecule [269, [274] [275] [276] [277] [278] . These small molecules are mostly peptidomimetic hydroxyethylene or hydroxymethylamine HIV-1 protease inhibitors. Other types of small molecules such as ADS-J1, ADS-J2, XTT formazan, NB-2, NB-64, AOP-RANTES, PSC-RANTES, Vicriviroc, Maraviroc and Aplaviroc are also the outcome of peptidomimetic approaches. They act by targeting the HIV-1 entry through gp120, gp41, CCR5 and CXCR4. This approach may be used in the future for other PPI as described above. 
